Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cladosporium

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Cladosporium. Displaying page 1 of 1.
    EudraCT Number: 2016-002844-18 Sponsor Protocol Number: 04071962 Start Date*: 2017-01-16
    Sponsor Name:Medical University of Vienna, Dpt. of Pediatrics
    Full Title: Preventive sublingual immunotherapy for house dust mite sensitized preschool children
    Medical condition: Patients; children at age 4 years with house dust mite IgE sensitization without allergic disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000190-81 Sponsor Protocol Number: TIPP Start Date*: 2021-12-29
    Sponsor Name:Goethe-University Frankfurt
    Full Title: A prospective multicenter placebo-controlled trial to study the efficacy and safety of Tiotropium in preventing severe asthma exacerbations in partial and uncontrolled preschool asthma. TIPP-Study
    Medical condition: Severe asthma exacerbations in partial and uncontrolled preschool asthma
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2007-006551-39 Sponsor Protocol Number: SP2007-31 Start Date*: 2008-01-23
    Sponsor Name:Resistentia Pharmaceuticals AB
    Full Title: A randomized, double-blind, placebo-controlled dose selection study with two RP 01 formulations evaluating anti-IgE immunotherapy in allergic patients
    Medical condition: Allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001738 Allergy LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010937-38 Sponsor Protocol Number: CIGE025AFR05 Start Date*: 2015-01-28
    Sponsor Name:Novartis Pharma S.A.S.
    Full Title: A 16-week treatment, multicenter, randomized, double blind, placebo-controlled, parallel-group study to assess the effect of omalizumab on the expression of FcεRI receptors of blood basophils and d...
    Medical condition: severe persistent non-atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005321-78 Sponsor Protocol Number: CQAW039X2201 Start Date*: 2013-04-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study evaluating efficacy and safety of QAW039 in the treatment of patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005939-15 Sponsor Protocol Number: DC04/RUP/3/08 Start Date*: 2009-02-11
    Sponsor Name:J. Uriach y Compañía, S.A.
    Full Title: Efficacy and safety of rupatadine in persistent allergic rhinitis and health-related quality of life in children age 6-11 years: A randomized, double blind, placebo-controlled clinical trial.
    Medical condition: Persistent Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034382 Perennial allergic rhinitis LLT
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 17:58:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA